152 related articles for article (PubMed ID: 12873656)
1. Prospective study of fibrinolytic markers and venous thromboembolism.
Folsom AR; Cushman M; Heckbert SR; Rosamond WD; Aleksic N
J Clin Epidemiol; 2003 Jun; 56(6):598-603. PubMed ID: 12873656
[TBL] [Abstract][Full Text] [Related]
2. Plasma from patients with vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation.
Keragala CB; McFadyen JD; Ho H; McCutcheon FM; Liu Z; Stevens H; Monagle P; Chunilal S; Medcalf RL; Tran H
J Thromb Haemost; 2024 Mar; 22(3):785-793. PubMed ID: 37944898
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
[TBL] [Abstract][Full Text] [Related]
4. Hypofibrinolysis in atrial fibrillation.
Roldán V; Marín F; Marco P; Martínez JG; Calatayud R; Sogorb F
Am Heart J; 1998 Dec; 136(6):956-60. PubMed ID: 9842006
[TBL] [Abstract][Full Text] [Related]
5. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
[TBL] [Abstract][Full Text] [Related]
6. The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo.
Jones CI; Payne DA; Hayes PD; Naylor AR; Bell PR; Thompson MM; Goodall AH
J Vasc Surg; 2008 Sep; 48(3):715-22. PubMed ID: 18572351
[TBL] [Abstract][Full Text] [Related]
7. Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism.
Bozic M; Stegnar M; Fermo I; Ritonja A; Peternel P; Stare J; D'Angelo A
Thromb Res; 2000 Nov; 100(4):271-8. PubMed ID: 11113270
[TBL] [Abstract][Full Text] [Related]
8. Plasmin-a2-plasmin inhibitor complex in plasma of patients with thromboembolic diseases.
Wada K; Takahashi H; Tatewaki W; Takizawa S; Shibata A
Thromb Res; 1989 Dec; 56(6):661-5. PubMed ID: 2534445
[TBL] [Abstract][Full Text] [Related]
9. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
[TBL] [Abstract][Full Text] [Related]
10. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
11. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
12. Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis.
Vuckovic BA; Djeric MJ; Tomic BV; Djordjevic VJ; Bajkin BV; Mitic GP
Blood Coagul Fibrinolysis; 2018 Jan; 29(1):19-24. PubMed ID: 28777103
[TBL] [Abstract][Full Text] [Related]
13. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis.
Barcellona D; Fenu L; Cauli C; Pisu G; Marongiu F
Thromb Haemost; 2003 Dec; 90(6):1061-4. PubMed ID: 14652637
[TBL] [Abstract][Full Text] [Related]
14. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
Crowther MA; Roberts J; Roberts R; Johnston M; Stevens P; Skingley P; Patrassi GM; Sartori MT; Hirsh J; Prandoni P; Weitz JI; Gent M; Ginsberg JS
Thromb Haemost; 2001 Mar; 85(3):390-4. PubMed ID: 11307802
[TBL] [Abstract][Full Text] [Related]
16. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).
Ohira T; Cushman M; Tsai MY; Zhang Y; Heckbert SR; Zakai NA; Rosamond WD; Folsom AR
J Thromb Haemost; 2007 Jul; 5(7):1455-61. PubMed ID: 17425663
[TBL] [Abstract][Full Text] [Related]
17. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis.
Comerota AJ; Chouhan V; Harada RN; Sun L; Hosking J; Veermansunemi R; Comerota AJ; Schlappy D; Rao AK
Ann Surg; 1997 Sep; 226(3):306-13; discussion 313-4. PubMed ID: 9339937
[TBL] [Abstract][Full Text] [Related]
18. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Coagulation and Fibrinolysis Markers for Predicting Postoperative Venous Thromboembolism in Total Joint Arthroplasty Patients.
Cheng Y; Liu J; Su Y; Zhao H; Zhao Y; Wen M; Lu S; Zhang W; Wu J
Clin Appl Thromb Hemost; 2019; 25():1076029619877458. PubMed ID: 31608652
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings.
Páramo JA; Orbe J; Fernández J
Thromb Haemost; 2001 Aug; 86(2):636-9. PubMed ID: 11522015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
